IP Library Granted Patent US 9,393,291
Granted Patent B2
US 9,393,291 · App. 13/862,206 · Granted Jul 19, 2016

Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,393,291
App. No.
13/862,206
Granted
Jul 19, 2016
Kind
B2
Abstract

Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases.

Claims (22)

1. A method of increasing cerebral blood flow in a patient having impaired cerebral blood flow comprising the steps of:

a. identifying a subject with an impairment of cerebral blood flow;

b. injecting a botulinum toxin preparation within a defined dose range into the extra cranial region of the head or neck of said patient;

c. allowing the botulinum toxin to spread within the deep brain structure and cause increased cerebral blood flow;

d. thereby preventing progression of or enhancing recovery from the impaired cerebral blood flow.

2. The method of claim 1 in which the impairment of cerebral blood flow is stroke.

3. The method of claim 1 in which the cause of impaired cerebral blood flow is brain vascular bed development impairment.

4. The method of claim 3 , wherein the brain vascular bed development impairment is hypoxic ischemic encephalopathy.

5. The method of claim 1 in which the impairment of cerebral blood flow is secondary to diabetes mellitus.

6. The method of claim 1 in which the impairment of cerebral blood flow is due to carotid artery disease.

7. The method of claim 1 in which impairment of cerebral blood flow is due to aneurysm.

8. The method of claim 1 in which impairment of cerebral blood flow is due to hypertension.

9. The method of claim 1 in which impairment of cerebral blood flow is due to Parry Rhomberg Syndrome.

10. A method of claim 1 , further comprising the step of localizing treatment based on neuroimaging analysis.

11. The method of claim 10 , in which the impairment of cerebral blood flow is stroke.

12. The method of claim 10 , in which the cause of impaired cerebral blood flow is brain vascular bed development impairment.

13. The method of claim 12 , wherein the brain vascular bed development impairment is hypoxic ischemic encephalopathy.

14. The method of claim 10 , in which the impairment of cerebral blood flow is secondary to diabetes mellitus.

15. The method of claim 10 , in which the impairment of cerebral blood flow is due to carotid artery disease.

16. The method of claim 10 , in which impairment of cerebral blood flow is due to aneurysm.

17. The method of claim 10 , in which impairment of cerebral blood flow is due to hypertension.

18. The method of claim 10 , in which impairment of cerebral blood flow is due to Parry Rhomberg Syndrome.

Assignments (7)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 038870/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2016
From: BORODIC, GARY E, DR; ACQUADRO, MARTIN A, DR
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 038249/0697 →